The Mumbai based leading pharma company Lupin Ltd has received Euro 20 million from Laboratories Servier of France for the sale of additional patent rights for Perindopril.

"This income significantly boosts our performance for the current year. We are very pleased with the transaction and it goes a long way to further demonstrate our IP capabilities" said Dr Kamal K Sharma, managing director, Lupin Ltd.

The company has state of the art R&D centre in Pune. It has a programme for developing New Chemical Entities (NCE). Lupin is a leading global player in anti-TB, cephalosporins (anti-infectives) and cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and asthma.